CHENGDU, China, July 8, 2011 /PRNewswire-Asia-FirstCall/ —
Tianyin Pharmaceutical Co., Inc. (NYSE Amex:
TPI), a pharmaceutical company that specializes in patented
biopharmaceutical medicine, modernized traditional Chinese
medicine, branded generics and active pharmaceutical ingredients
(API) today announced that its 250-ton Jiangchuan Macrolide
facility (JCM) is scheduled for its manufacturing test runs by the
end of July.
The test runs prepare the production lines for the final Good
Manufacturing Practice (GMP) certification process by conducting a
series of operations and tests under actual or simulated operating
conditions to verify its performance, efficiency, reliability and
safety of the Azithromycin API manufacturing at JCM.
The successful completion of the test runs will be immediately
followed by the GMP certification at JCM.
About GMP
Good Manufacturing Practice (GMP), widely adopted worldwide,
provide guidelines covering the manufacture and testing of
pharmaceuticals and active pharmaceutical ingredients, diagnostics,
foods, pharmaceutical products, and medical devices with the basic
concepts that safeguard the health of the patient, producing a good
quality medicine, medical devices or active pharmaceutical
products. GMP guidelines are a series of general principles that
are mandated during manufacturing. The context of GMP covers plant
and equipment operation, personnel training, quality management,
product safety and stability along with other aspects that ensure
the quality the product (www.sfda.gov.cn, Chinese
version).
About TPI
Headquartered at Chengdu, China, TPI is a pharmaceutical company
that specializes in the development, manufacturing, marketing and
sales of patented biopharmaceutical, modernized traditional Chinese
medicines, branded generics and active pharmaceutical ingred
‘/>”/>
